Product
LNC1004
1 clinical trial
3 indications
Indication
Solid TumorIndication
UnspecifiedIndication
AdultClinical trial
Phase I, Open-Label Study of the Safety and Dosimetry of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in Adult Patients With Advanced Fibroblast Activation Protein (FAP)-Positive Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-10